Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents.

Authors :: Marconi G
Petracci E
Lanzarone G
Vetro C
Martelli MP
Papayannidis C
Audisio E
Minetto P
Riva C
Guolo F
Martini G
Zappasodi P
Vincenzo F
Gigli F
Griguolo D
Rondoni M
Ciotti G
Borlenghi E
Ciccone N
Palumbo FE
Nanni J
Mattei D
Bernardi M
Cignetti A
Zingaretti C
Vertogen B
Cerchione C
Lanza F
Cilloni D
Brunetti L
Palmieri R
Curti A
Giannini MB
Todisco E
Fracchiolla N
Martinelli G
Source :: American journal of hematology [Am J Hematol] 2025 Jan 20. Date of Electronic Publication: 2025 Jan 20.
Publication Year :: 2025
Publisher :: Ahead of Print
Abstract: Expectation of survival of patients receiving HMA + VEN is influenced by pre-treatment comorbidity burden.<br /> (© 2025 The Author(s). American Journal of Hematology published by Wiley Periodicals LLC.)

Full Text Access

Tools